[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
overnightstocks.com @overnight_stock on x XXX followers
Created: 2025-07-23 15:37:27 UTC
$REPL | Replimune rebounds despite FDA rejection and multiple downgrades | via
• Shares plummeted -XX% on Tuesday after FDA rejected RP1 application for advanced melanoma (combo with $BMY’s Opdivo) • Wednesday rebound: +24.24% despite analyst downgrades • BMO: Downgrade to Underperform, PT cut to $X • Barclays: Downgrade to Equal Weight, PT slashed to $X (from $17) • H.C. Wainwright: Downgrade to Neutral from Buy • Concerns over funding and need to rerun clinical trials per FDA feedback
XXX engagements
Related Topics $barcl rating agency $bmys stocks replimune $repl